查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701276

美國腦腫瘤市場規模、佔有率、趨勢分析報告（依腫瘤類型、治療類型、細分市場預測，2025-2034）

U.S. Brain Tumor Market Size, Share & Trends Analysis Report By Tumor Type (Malignant, Non-malignant), By Treatment Type (Surgery, Radiation Therapy, Interventional Device-Based Procedures, Chemotherapy), And Segment Forecasts, 2025 - 2034
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

美國腦瘤市場的成長與趨勢：

根據 Grand View Research 的新報告，美國腦瘤市場預計到 2034 年將達到 43.5 億美元，2025 年至 2034 年的複合年成長率為 9.87%。

例如，美國國家腦瘤協會的報告估計，目前約有 100 萬美國患有原發性腦瘤，這表明有大量患者需要有效治療方法。到 2023 年，這些腫瘤中約有 72% 將被歸類為良性，28% 將被歸類為惡性，這表明治療需求和方法多種多樣。此外，根據同一資訊來源，非惡性腦膜瘤是最常見的原發性非惡性腦腫瘤類型，約佔所有腦腫瘤的 39.7% 和所有非惡性腫瘤的 55.4%。

公共和私營部門不斷增加的資金和投資也在推動市場擴張，進一步促進市場成長。此外，標靶治療、免疫治療等治療方案的不斷創新以及手術技術的進步在市場擴張中發揮關鍵作用。精準醫療的突破使得更個人化的治療方案成為可能，改善了患者的治療效果並吸引了投資。

市場正處於高速成長階段，且成長速度正在加快。美國腦瘤市場呈現成長態勢，原因在於腦瘤發生率不斷上升，同時診斷工具不斷改進，標靶治療等治療方法創新不斷湧現，政府、非營利組織和私營部門對腦瘤研究投入大量資金，以及提供多種治療選擇，例如手術、放射線治療和化療。

美國腦瘤市場報告重點

  • 根據腫瘤類型，由於腦腫瘤盛行率上升以及膠質母細胞瘤和高級別惡性腦腫瘤發生率增加，預計惡性腫瘤部分將在 2024 年佔據最大的收入佔有率。
  • 惡性腦瘤，包括膠質母細胞瘤，通常需要積極的治療方法，通常結合手術、化療和放射線治療。
  • 根據治療類型，由於多種引人注目的因素，外科手術部分在 2024 年佔據了最大的市場佔有率。首先，手術介入仍然是治療多種類型腦瘤，尤其是膠質母細胞瘤等惡性腫瘤的主要方法。外科手術，包括開顱手術和腫瘤切除術，旨在盡可能切除腫瘤，這可以減輕腦部壓力，緩解症狀，並改善患者的整體預後。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國腦瘤市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國腦瘤市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國腦瘤市場：腫瘤類型估計與趨勢分析

  • 定義和範圍
  • 2024年及2034年腫瘤類型市場佔有率
  • 細分儀表板
  • 美國腦腫瘤市場：按腫瘤類型分類的展望
  • 2024-2034 年市場規模、預測與趨勢分析（按腫瘤類型治療的患者數量）
    • 惡性
    • 非惡性

第5章美國腦瘤市場：治療類型估計與趨勢分析

  • 定義和範圍
  • 2024 年和 2030 年各治療類型的市場佔有率
  • 細分儀表板
  • 美國腦瘤市場（按治療類型）展望
  • 惡性腫瘤治療類型市場規模、預測及趨勢分析（2024-2034）
    • 外科手術
    • 放射治療
    • 基於介入設備的程序
    • 化療
    • 標靶治療
    • 腫瘤治療中心（TTF）
    • 雷射間質熱療（LITT）
    • 手術標靶放射線治療
    • 導管式超音波熱凝固術
    • 聚焦超音波（FUS）
    • 低強度聚焦超音波（LIFU）
  • 非惡性腫瘤治療類型市場規模、預測與趨勢分析（2024-2034 年）
    • 外科手術
    • 放射治療
    • 其他監控設備

第6章競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
    • 創新者
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • GT Medical Technologies, Inc.
    • Novocure
    • ZAP Surgical Systems, Inc.
    • Aesculap, Inc.-a B. Braun company
    • Accuray Incorporated
    • Carthera
    • Alpheus Medical Inc.
    • Alpha Tau Medical Ltd
    • Elekta
    • IMRIS Inc.
    • Medtronic
    • Monteris
    • Openwater
    • Acoustic MedSystems, Inc.
    • NaviFUS Corp
    • Insightec
    • Varian Medical Systems, Inc.（Siemens Healthineers）
    • RefleXion
    • MagnetTx Oncology Solutions Ltd.
    • NICO Corporation（Stryker）
    • Terumo Interventional Systems
    • Boston Scientific Corporation
    • Koninklijke Philips NV
    • IBA Worldwide
Product Code: GVR-4-68040-534-5

U.S. Brain Tumor Market Growth & Trends:

The U.S. brain tumor market is anticipated to reach USD 4.35 billion by 2034, growing at a CAGR of 9.87% from 2025 to 2034, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of brain cancer and rising number of brain tumor diagnoses in the U.S. For instance, according to the National Brain Tumor Society report, an estimated one million Americans are currently living with a primary brain tumor, highlighting a substantial patient population in need of effective treatment options. Among these tumors, approximately 72% were classified as benign, while 28% were malignant in 2023, indicating a diverse range of treatment needs and approaches. Furthermore, according to the same source, non-malignant meningiomas represent the most prevalent type of primary non-malignant brain tumors, comprising approximately 39.7% of all brain tumors and 55.4% of all non-malignant tumors.

Increasing funding and investments from both public and private sectors are also driving market expansion and further fueling market growth. Furthermore, continued innovation in treatment options, including targeted therapies, immunotherapies, and advancements in surgical techniques is playing a crucial role in market expansion. Breakthroughs in precision medicine allow for more personalized treatment plans, which enhance patient outcomes and attract investment.

The market growth stage is high, and the pace of the market growth is accelerating. The U.S. brain tumor market is characterized by growth owing to the rising prevalence of brain tumors, along with better diagnostic tools, innovations in treatment modalities, such as targeted therapies, substantial funding for brain tumor research from government, non-profits, and private sectors, and availability of a wide range of treatment options, including surgery, radiation therapy, and chemotherapy, among others.

U.S. Brain Tumor Market Report Highlights:

  • Based on tumor type, the malignant segment accounted for the largest revenue share in 2024 driven by the rising prevalence of brain cancer and increasing incidence of glioblastoma and high-grade malignant brain tumors
  • Malignant brain tumors, including glioblastomas, often require aggressive treatment approaches, which typically involve a combination of surgery, chemotherapy, and radiation therapy
  • Based on treatment type, the surgery segment accounted for the largest market share in 2024 due to several compelling factors. Firstly, surgical intervention remains the primary approach for managing many types of brain tumors, particularly malignant tumors such as glioblastomas. Surgical procedures, including craniotomy and tumor resection, aim to remove as much of the tumor as possible, which can relieve pressure on the brain, alleviate symptoms, and improve overall patient outcomes

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research in the U.S.
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Tumor Type outlook
    • 2.2.2. Treatment Type outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Brain Tumor Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of primary and secondary brain tumors
      • 3.2.1.2. Innovations in diagnostic imaging, surgical techniques (such as advanced neurosurgery), and therapeutic modalities (such as targeted therapies, immunotherapies, and radiotherapy)
      • 3.2.1.3. Increasing awareness and early diagnosis of brain tumor
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Side effects and complications associated with brain tumor treatrment
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Increasing number of clinical trials
      • 3.2.3.2. Rising fundings and investments from both public and private sectors in research and development activities
    • 3.2.4. Market challenge analysis
      • 3.2.4.1. Product recalls
      • 3.2.4.2. Stringent regulations
  • 3.3. U.S. Brain tumor Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Brain Tumor Market: Tumor Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Tumor Type Market Share, 2024 & 2034
  • 4.3. Segment Dashboard
  • 4.4. U.S. Brain Tumor Market by Tumor Type Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1. Malignant
      • 4.5.1.1. Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.2. Glioblastomas
        • 4.5.1.2.1. Glioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.3. Medulloblastomas
        • 4.5.1.3.1. Medulloblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.4. Astrocytomas
        • 4.5.1.4.1. Astrocytomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.5. Ependymomas
        • 4.5.1.5.1. Ependymomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.6. Others
        • 4.5.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2. Non-Malignant
      • 4.5.2.1. Non-Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.2. Meningiomas
        • 4.5.2.2.1. Meningiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.3. Pituitary Adenomas
        • 4.5.2.3.1. Pituitary Adenomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.4. Craniopharyngiomas
        • 4.5.2.4.1. Craniopharyngiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.5. Hemangioblastomas
        • 4.5.2.5.1. Hemangioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.6. Others
        • 4.5.2.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)

Chapter 5. U.S. Brain Tumor Market: Treatment Type Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Treatment Type Market Share, 2024 & 2030
  • 5.3. Segment Dashboard
  • 5.4. U.S. Brain Tumor Market by Treatment Type Outlook
  • 5.5. Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
    • 5.5.1. Surgery
      • 5.5.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 5.5.1.2. Neurosurgical Instruments
        • 5.5.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.3. Robotic Surgery Systems
        • 5.5.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.4. Interventional Device-Based Procedures
        • 5.5.1.4.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.5. Endoscopes
        • 5.5.1.5.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.6. Intraoperative Imaging Systems
        • 5.5.1.6.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.7. Others
        • 5.5.1.7.1. Others market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.2. Radiation Therapy
      • 5.5.2.1. Radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
        • 5.5.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.2.2.2. Linear Accelerators (LINAC)
          • 5.5.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.2.2.3. Gamma Knife Systems
          • 5.5.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.2.2.4. Proton radiosurgery
          • 5.5.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.3. Internal radiation/Brachytherapy devices
        • 5.5.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.3. Interventional Device-Based Procedures
      • 5.5.3.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.3.2. Embolization Devices
        • 5.5.3.2.1. Embolization devices market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.3.2.2. Liquid Embolic Agents
          • 5.5.3.2.2.1. Liquid embolic agents market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.3.2.3. Microspheres
          • 5.5.3.2.3.1. Microspheres market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.3.3. Tumor Ablation Devices
        • 5.5.3.3.1. Tumor ablation devices market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.4. Chemotherapy
      • 5.5.4.1. Chemotherapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.5. Targeted Therapy
      • 5.5.5.1. Targeted therapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.6. Tumor Treating Fields (TTF)
      • 5.5.6.1. Tumor Treating Fields (TTF) market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.7. Laser Interstitial Thermal Therapy (LITT)
      • 5.5.7.1. Laser Interstitial Thermal Therapy (LITT) market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.8. Surgically Targeted Radiation Therapy
      • 5.5.8.1. Surgically targeted radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.9. Catheter-Based Ultrasound Thermal Ablation
      • 5.5.9.1. Catheter-based ultrasound thermal ablation market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.10. Focused Ultrasound (FUS)
      • 5.5.10.1. Focused Ultrasound (FUS) market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.11. Low-Intensity Focused Ultrasound (LIFU)
      • 5.5.11.1. Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast 2024 to 2034 (USD Million)
  • 5.6. Non-Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
    • 5.6.1. Surgery
      • 5.6.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 5.6.1.2. Neurosurgical Instruments
        • 5.6.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.1.2.2. Blade, Knife, Cutter & Scissors
          • 5.6.1.2.2.1. Blade, knife, cutter & scissors market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.1.2.3. Dissector
          • 5.6.1.2.3.1. Dissector market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.1.2.4. Drill & Perforator
          • 5.6.1.2.4.1. Drill & perforator market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.1.2.5. Others
          • 5.6.1.2.5.1. Others market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.3. Robotic Surgery Systems
        • 5.6.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.4. Endoscopes
        • 5.6.1.4.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.5. Intraoperative Imaging Systems
        • 5.6.1.5.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.6. Others
        • 5.6.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.2. Radiation Therapy
      • 5.6.2.1. Radiation Therapy market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
        • 5.6.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.2.2.2. Linear Accelerators (LINAC)
          • 5.6.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.2.2.3. Gamma Knife Systems
          • 5.6.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.2.2.4. Proton radiosurgery
          • 5.6.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.3. Internal radiation/Brachytherapy Devices
        • 5.6.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.3. Other Monitoring Devices
      • 5.6.3.1. Other monitoring devices market estimates and forecast 2024 to 2034 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
    • 6.2.1. Innovators
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2024
    • 6.3.4. GT Medical Technologies, Inc.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Novocure
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. ZAP Surgical Systems, Inc.
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Aesculap, Inc. - a B. Braun company
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Accuray Incorporated
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Carthera
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Alpheus Medical Inc.
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Alpha Tau Medical Ltd
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. Elekta
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives
    • 6.3.13. IMRIS Inc.
      • 6.3.13.1. Company overview
      • 6.3.13.2. Financial performance
      • 6.3.13.3. Product benchmarking
      • 6.3.13.4. Strategic initiatives
    • 6.3.14. Medtronic
      • 6.3.14.1. Company overview
      • 6.3.14.2. Financial performance
      • 6.3.14.3. Product benchmarking
      • 6.3.14.4. Strategic initiatives
    • 6.3.15. Monteris
      • 6.3.15.1. Company overview
      • 6.3.15.2. Financial performance
      • 6.3.15.3. Product benchmarking
      • 6.3.15.4. Strategic initiatives
    • 6.3.16. Openwater
      • 6.3.16.1. Company overview
      • 6.3.16.2. Financial performance
      • 6.3.16.3. Product benchmarking
      • 6.3.16.4. Strategic initiatives
    • 6.3.17. Acoustic MedSystems, Inc.
      • 6.3.17.1. Company overview
      • 6.3.17.2. Financial performance
      • 6.3.17.3. Product benchmarking
      • 6.3.17.4. Strategic initiatives
    • 6.3.18. NaviFUS Corp
      • 6.3.18.1. Company overview
      • 6.3.18.2. Financial performance
      • 6.3.18.3. Product benchmarking
      • 6.3.18.4. Strategic initiatives
    • 6.3.19. Insightec
      • 6.3.19.1. Company overview
      • 6.3.19.2. Financial performance
      • 6.3.19.3. Product benchmarking
      • 6.3.19.4. Strategic initiatives
    • 6.3.20. Varian Medical Systems, Inc. (Siemens Healthineers)
      • 6.3.20.1. Company overview
      • 6.3.20.2. Financial performance
      • 6.3.20.3. Product benchmarking
      • 6.3.20.4. Strategic initiatives
    • 6.3.21. RefleXion
      • 6.3.21.1. Company overview
      • 6.3.21.2. Financial performance
      • 6.3.21.3. Product benchmarking
      • 6.3.21.4. Strategic initiatives
    • 6.3.22. MagnetTx Oncology Solutions Ltd.
      • 6.3.22.1. Company overview
      • 6.3.22.2. Financial performance
      • 6.3.22.3. Product benchmarking
      • 6.3.22.4. Strategic initiatives
    • 6.3.23. NICO Corporation (Stryker)
      • 6.3.23.1. Company overview
      • 6.3.23.2. Financial performance
      • 6.3.23.3. Product benchmarking
      • 6.3.23.4. Strategic initiatives
    • 6.3.24. Terumo Interventional Systems
      • 6.3.24.1. Company overview
      • 6.3.24.2. Financial performance
      • 6.3.24.3. Product benchmarking
      • 6.3.24.4. Strategic initiatives
    • 6.3.25. Boston Scientific Corporation
      • 6.3.25.1. Company overview
      • 6.3.25.2. Financial performance
      • 6.3.25.3. Product benchmarking
      • 6.3.25.4. Strategic initiatives
    • 6.3.26. Koninklijke Philips N.V.
      • 6.3.26.1. Company overview
      • 6.3.26.2. Financial performance
      • 6.3.26.3. Product benchmarking
      • 6.3.26.4. Strategic initiatives
    • 6.3.27. IBA Worldwide
      • 6.3.27.1. Company overview
      • 6.3.27.2. Financial performance
      • 6.3.27.3. Product benchmarking
      • 6.3.27.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Brain Tumor market, by Treatment Type 2024 - 2034 (USD Million)
  • Table 4 U.S. Brain Tumor market, by Tumor Type 2024 - 2034 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. brain tumor market: Market snapshot
  • Fig. 9 U.S. brain tumor market: Market segmentation
  • Fig. 10 U.S. brain tumor market: Strategy framework
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 U.S. brain tumor market driver impact
  • Fig. 14 U.S. brain tumor market restraint impact
  • Fig. 15 U.S. brain tumor market porter's five forces analysis
  • Fig. 16 U.S. brain tumor market PESTEL analysis
  • Fig. 17 U.S. brain tumor market segment dashboard
  • Fig. 18 U.S. brain tumor market: Tumor type movement Analysis
  • Fig. 19 Malignant brain tumor market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 20 Non-malignant brain tumor market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 21 U.S. brain tumor market: Treatment type (malignant) movement Analysis
  • Fig. 22 Surgery market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 23 Radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 24 Interventional device-based procedures market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 25 Chemotherapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 26 Targeted therapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 27 Tumor Treating Fields (TTF) market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 28 Laser Interstitial Thermal Therapy (LITT) market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 29 Surgically targeted radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 30 Catheter-based ultrasound thermal ablation market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 31 Focused Ultrasound (FUS) market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 32 Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 33 U.S. brain tumor market: Treatment type (non-malignant) movement Analysis
  • Fig. 34 Surgery market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 35 Radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 36 Other monitoring devices market estimates and forecast, 2024 - 2034 (USD Million)